BioCryst Presents New Real-world Evidence Showing Reductions in Attack Rates in HAE Patients with Normal C1-Inhibitor after Beginning ORLADEYO® (berotralstat) Treatment
In a recent presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress in Valencia, Spain, BioCryst Pharmaceuticals, Inc. revealed groundbreaking real-world evidence indicating a decrease in monthly attack rates among hereditary angioedema (HAE) patients with normal C1-inhibitor (HAE-nC1-INH) levels and function following the initiation of ORLADEYO® (berotralstat) treatment. Dr. Isabelle Boccon-Gibod from Grenoble Alps University Hospital presented the findings, emphasizing the clinical significance of this data.
Six patients with HAE-nC1-INH participated in the analysis, with five patients experiencing a notable 75 to 100 percent reduction in their HAE attack rate after six months of berotralstat treatment. Additionally, one patient, who was concurrently using tranexamic acid, saw a 29 percent decrease in their attack rate. Notably, adverse events related to berotralstat were minimal, with only one patient reporting mild gastrointestinal symptoms that improved over time.
Furthermore, a separate study presented at EAACI highlighted the adverse health outcomes associated with the use of attenuated androgens for HAE prophylaxis. The research underscored the need for safer and more tolerable prophylactic options in light of the serious risks linked to androgen use, including increased cardiovascular events, liver damage, and cancer. The study recommended targeted HAE therapies as the preferred first-line long-term prophylaxis, with androgens reserved for second-line use.
Overall, these findings shed light on the importance of access to innovative HAE treatments like ORLADEYO® (berotralstat) and emphasize the critical role of evidence-based medicine in guiding treatment decisions for patients with HAE.
For more information about BioCryst Pharmaceuticals and their commitment to developing therapies for rare diseases, please visit www.biocryst.com.
